Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report

Clin Lung Cancer. 2019 Jul;20(4):e514-e516. doi: 10.1016/j.cllc.2019.04.013. Epub 2019 Apr 28.

Authors

Giacomo Bertelli¹, Rosalinda Trovato¹, Stefano Ugel², Emilio Bria³, Michele Milella⁴, Vincenzo Bronte¹, Sara Pilotto⁴

Affiliations

¹ Immunology Section, Department of Medicine, Verona University Hospital, Verona, Italy.
² Immunology Section, Department of Medicine, Verona University Hospital, Verona, Italy. Electronic address: [email protected].
³ Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; Università Cattolica Del Sacro Cuore, Roma, Italy.
⁴ Medical Oncology, University of Verona, Verona University Hospital, Verona, Italy.

PMID: 31122866
DOI: 10.1016/j.cllc.2019.04.013

No abstract available

Keywords: Immunotherapy; MDSC; NSCLC; Predictive biomarkers; Tumor-induced immunosuppression.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma of Lung / diagnosis*
Adenocarcinoma of Lung / therapy
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors
Female
Humans
Immunomodulation
Immunotherapy / methods*
Lung Neoplasms / diagnosis*
Lung Neoplasms / therapy
Middle Aged
Myeloid-Derived Suppressor Cells / immunology*
Neoplasm Staging
Prognosis

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
durvalumab